

Thomas Powles

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1321932/publications.pdf>

Version: 2024-02-01

252
papers

41,540
citations

12303

69
h-index

2675

193
g-index

259
all docs

259
docs citations

259
times ranked

28204
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient-reported Outcomes from JAVELIN Bladder 100: Avelumab First-line Maintenance Plus Best Supportive Care Versus Best Supportive Care Alone for Advanced Urothelial Carcinoma. <i>European Urology</i> , 2023, 83, 320-328.	0.9	16
2	Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 Trial. <i>European Urology Oncology</i> , 2022, 5, 225-234.	2.6	17
3	First-line Nivolumab plus Ipilimumab Versus Sunitinib in Patients Without Nephrectomy and With an Evaluable Primary Renal Tumor in the CheckMate 214 Trial. <i>European Urology</i> , 2022, 81, 266-271.	0.9	33
4	Avelumab in locally advanced or metastatic urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, , .	1.1	1
5	Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. <i>Nature Medicine</i> , 2022, 28, 144-153.	15.2	102
6	Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis. <i>International Journal of Clinical Oncology</i> , 2022, 27, 383-395.	1.0	8
7	2021 Updated European Association of Urology Guidelines on the Use of Adjuvant Pembrolizumab for Renal Cell Carcinoma. <i>European Urology</i> , 2022, 81, 134-137.	0.9	29
8	Primary results of STRONG: An open-label, multicenter, phase 3b study of fixed-dose durvalumab monotherapy in previously treated patients with urinary tract carcinoma. <i>European Journal of Cancer</i> , 2022, 163, 55-65.	1.3	5
9	Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102360.	3.4	22
10	Clinico-genomic characterization of patients with metastatic urothelial carcinoma in real-world practice and development of a novel bladder immune prognostic index (BIPI).. <i>Journal of Clinical Oncology</i> , 2022, 40, 548-548.	0.8	1
11	Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 350-350.	0.8	18
12	Association of TMB and PD-L1 with efficacy of first-line pembrolizumab (pembro) or pembro + chemotherapy (chemo) versus chemo in patients (pts) with advanced urothelial carcinoma (UC) from KEYNOTE-361.. <i>Journal of Clinical Oncology</i> , 2022, 40, 540-540.	0.8	1
13	Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 275.	3.4	75
14	The effect of anti-cancer therapy on immunological response to COVID-19 vaccination.. <i>Journal of Clinical Oncology</i> , 2022, 40, 319-319.	0.8	1
15	Study EV-302: A two-arm, open-label, randomized controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated advanced urothelial carcinoma (aUC) (trial in progress).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS589-TPS589.	0.8	15
16	Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2022, 40, 290-290.	0.8	22
17	Molecular residual disease (MRD) detection with a tissue comprehensive genomic profiling (CGP)-informed personalized monitoring assay: An exploratory analysis of the IMvigor-010 observation arm.. <i>Journal of Clinical Oncology</i> , 2022, 40, 448-448.	0.8	2
18	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up results from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 487-487.	0.8	23

#	ARTICLE	IF	CITATIONS
19	Impact of Circulating Tumor DNA-Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors. <i>JCO Precision Oncology</i> , 2022, 6, e2100181.	1.5	33
20	Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma. , 2022, 10, e004316.		45
21	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. <i>European Urology</i> , 2022, 82, 399-410.	0.9	485
22	Conditional survival and long-term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma. <i>Cancer</i> , 2022, 128, 2085-2097.	2.0	103
23	Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial. <i>Nature Communications</i> , 2022, 13, 1878.	5.8	3
24	From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. <i>Clinical Cancer Research</i> , 2022, 28, 831-839.	3.2	12
25	Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer. <i>Future Oncology</i> , 2022, 18, 2361-2371.	1.1	4
26	Putative Biomarkers of Clinical Benefit With Pembrolizumab in Advanced Urothelial Cancer: Results from the KEYNOTE-045 and KEYNOTE-052 Landmark Trials. <i>Clinical Cancer Research</i> , 2022, 28, 2050-2060.	3.2	21
27	Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. <i>European Urology</i> , 2022, 82, 212-222.	0.9	56
28	Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4575-4575.	0.8	1
29	Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2022, 23, 888-898.	5.1	114
30	Cabozantinib (C) in combination with atezolizumab (A) in urothelial carcinoma (UC): Results from Cohorts 3, 4, 5 of the COSMIC-021 study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4504-4504.	0.8	3
31	Association between depth of response (DepOR) and clinical outcomes: Exploratory analysis in patients with previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 9ER.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4501-4501.	0.8	5
32	A randomised, double blind, phase II clinical trial of maintenance cabozantinib following chemotherapy for metastatic urothelial carcinoma (mUC): Final analysis of the ATLANTIS cabozantinib comparison.. <i>Journal of Clinical Oncology</i> , 2022, 40, LBA4505-LBA4505.	0.8	6
33	Cross-trial validation of molecular subtypes in patients with metastatic clear cell renal cell carcinoma (RCC): The JAVELIN Renal 101 experience.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4531-4531.	0.8	3
34	Long-term outcomes in patients with advanced urothelial carcinoma (UC) who received avelumab first-line (1L) maintenance with or without second-line (2L) treatment: Exploratory analyses from JAVELIN Bladder 100.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4560-4560.	0.8	5
35	Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4516-4516.	0.8	13
36	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (aUC): Long-term outcomes from JAVELIN Bladder 100 in subgroups defined by response to 1L chemotherapy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4559-4559.	0.8	5

#	ARTICLE	IF	CITATIONS
37	A phase 3 study of the subcutaneous programmed cell death protein 1 inhibitor sasanlimab as single agent for patients with bacillus Calmette-Guérin, unresponsive high-risk, non-muscle invasive bladder cancer: CREST Study Cohort B.. Journal of Clinical Oncology, 2022, 40, TPS4614-TPS4614.	0.8	2
38	Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. European Urology, 2022, 82, 427-439.	0.9	15
39	Partial Response and Stable Disease Correlate with Positive Outcomes in Atezolizumab-treated Patients with Advanced Urinary Tract Carcinoma. European Urology Focus, 2021, 7, 1084-1091.	1.6	4
40	Atezolizumab plus Bevacizumab Versus Sunitinib for Patients with Untreated Metastatic Renal Cell Carcinoma and Sarcomatoid Features: A Prespecified Subgroup Analysis of the IMmotion151 Clinical Trial. European Urology, 2021, 79, 659-662.	0.9	64
41	Reply to Alessia Cimadamore, Liang Cheng, Marina Scarpelli, et al.'s Letter to the Editor re: Alfonso Gómez de Liaño Lista, Nick van Dijk, Guillermo de Velasco Oria de Rueda, et al. Clinical Outcome After Progressing to Frontline and Second-line Anti-PD-1/PD-L1 in Advanced Urothelial Cancer. Eur Urol 2020;77:269-76. Progression and Hyperprogression Versus Pseudoprogression: Morphologic Documentation. European Urology, 2021, 79, e20-e21.	0.9	0
42	Neoadjuvant and Adjuvant Chemotherapy for Upper Tract Urothelial Carcinoma: A 2020 Systematic Review and Meta-analysis, and Future Perspectives on Systemic Therapy. European Urology, 2021, 79, 635-654.	0.9	102
43	Summary from the Kidney Cancer Association's Inaugural Think Thank: Coalition for a Cure. Clinical Genitourinary Cancer, 2021, 19, 167-175.	0.9	4
44	Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 78-86.	3.2	154
45	Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study. Clinical Cancer Research, 2021, 27, 3360-3369.	3.2	47
46	Avelumab (Ave) first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): JAVELIN Bladder 100 Japanese subgroup analysis.. Journal of Clinical Oncology, 2021, 39, 425-425.	0.8	2
47	Perioperative therapy in renal cancer in the era of immune checkpoint inhibitor therapy. Current Opinion in Urology, 2021, 31, 262-269.	0.9	16
48	Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. New England Journal of Medicine, 2021, 384, 829-841.	13.9	961
49	Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. New England Journal of Medicine, 2021, 384, 1125-1135.	13.9	473
50	Immune Checkpoint Inhibitors in Front-line Therapy for Urothelial Cancer. European Urology Oncology, 2021, 4, 943-947.	2.6	11
51	Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 2021, 79, 339-342.	0.9	98
52	Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma. New England Journal of Medicine, 2021, 384, 1289-1300.	13.9	956
53	Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, The, 2021, 22, 525-537.	5.1	225
54	Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade. , 2021, 9, e002231.		69

#	ARTICLE	IF	CITATIONS
55	An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer. <i>Nature Medicine</i> , 2021, 27, 793-801.	15.2	56
56	Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp I± in combination with atezolizumab ± bevacizumab in patients with unresectable advanced/metastatic renal cell carcinoma (RCC) (NCT03063762).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4556-4556.	0.8	5
57	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4527-4527.	0.8	11
58	Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4525-4525.	0.8	3
59	Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4539-4539.	0.8	9
60	Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4520-4520.	0.8	8
61	Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).. <i>Journal of Clinical Oncology</i> , 2021, 39, 4573-4573.	0.8	1
62	Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.. <i>Journal of Clinical Oncology</i> , 2021, 39, LBA5-LBA5.	0.8	26
63	Patient outcomes following disease progression with enfortumab-vedotin (EV) in metastatic urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2021, 39, e16516-e16516.	0.8	1
64	Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial. <i>European Urology</i> , 2021, 79, 665-673.	0.9	20
65	Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L) Tj ETQq1 1 0784314 rgBT /Ove	0.8	14
66	Toxicity and Surgical Complication Rates of Neoadjuvant Atezolizumab in Patients with Muscle-invasive Bladder Cancer Undergoing Radical Cystectomy: Updated Safety Results from the ABACUS Trial. <i>European Urology Oncology</i> , 2021, 4, 456-463.	2.6	18
67	Molecular determinants of response to PD-L1 blockade across tumor types. <i>Nature Communications</i> , 2021, 12, 3969.	5.8	79
68	Immune Checkpoint Inhibition in Advanced Bladder and Kidney Cancer: Responses and Further Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e182-e189.	1.8	7
69	ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. <i>Nature</i> , 2021, 595, 432-437.	13.7	293
70	Radiomics for Renal Cell Carcinoma: Predicting Outcomes from Immunotherapy and Targeted Therapies—A Narrative Review. <i>European Urology Focus</i> , 2021, 7, 717-721.	1.6	11
71	Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 931-945.	5.1	337
72	Abstract CT188: IMmotion151: updated overall survival (OS) and exploratory analysis of the association of gene expression and clinical outcomes with atezolizumab plus bevacizumab vs sunitinib in patients with locally advanced or metastatic renal cell carcinoma (mRCC). <i>Cancer Research</i> , 2021, 81, CT188-CT188.	0.4	3

#	ARTICLE	IF	CITATIONS
73	Atezolizumab Versus Chemotherapy in Patients with Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: A Long-term Overall Survival and Safety Update from the Phase 3 IMvigor211 Clinical Trial. <i>European Urology</i> , 2021, 80, 7-11.	0.9	60
74	First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 151, 35-48.	1.3	24
75	Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice. <i>Journal of Urology</i> , 2021, 206, 240-251.	0.2	7
76	Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study. <i>Clinical Genitourinary Cancer</i> , 2021, 19, 354-361.	0.9	5
77	Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2021, 385, 683-694.	13.9	394
78	Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma. <i>BMC Cancer</i> , 2021, 21, 904.	1.1	10
79	Beyond Chemotherapy and Checkpoint Inhibitors: Weighing the Risks and Benefits of the Novel Therapies for Metastatic Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01430.	0.8	3
80	Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2021, 99, 102242.	3.4	13
81	The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor-based Combination Therapies for Treatment-naïve Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care. <i>European Urology</i> , 2021, 80, 393-397.	0.9	103
82	Treatment-free Survival after Immune Checkpoint Inhibitor Therapy versus Targeted Therapy for Advanced Renal Cell Carcinoma: 42-Month Results of the CheckMate 214 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 6687-6695.	3.2	25
83	Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial. <i>Nature Medicine</i> , 2021, 27, 2200-2211.	15.2	65
84	Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted Therapy. <i>European Urology Focus</i> , 2020, 6, 999-1005.	1.6	5
85	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
86	Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer. <i>European Urology</i> , 2020, 77, 269-276.	0.9	45
87	The evolving role of PD-L1 testing in patients with metastatic urothelial carcinoma. <i>Cancer Treatment Reviews</i> , 2020, 82, 101925.	3.4	73
88	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 105-120.	5.1	61
89	The Impact of the COVID-19 Pandemic on Genitourinary Cancer Care: Re-envisioning the Future. <i>European Urology</i> , 2020, 78, 731-742.	0.9	39
90	Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1563-1573.	5.1	466

#	ARTICLE	IF	CITATIONS
91	Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. , 2020, 8, e000891.		160
92	Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open, 2020, 5, e001079.	2.0	343
93	Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder. European Urology Oncology, 2020, 3, 728-738.	2.6	61
94	Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2020, 21, 1574-1588.	5.1	324
95	Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. New England Journal of Medicine, 2020, 383, 1218-1230.	13.9	802
96	Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine, 2020, 26, 1733-1741.	15.2	282
97	Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade. Cancer Cell, 2020, 38, 803-817.e4.	7.7	262
98	Health-related quality of life in the randomized phase 3 study of ramucirumab plus docetaxel versus placebo plus docetaxel in platinum-refractory advanced urothelial carcinoma (RANGE). BMC Urology, 2020, 20, 181.	0.6	6
99	High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nature Medicine, 2020, 26, 693-698.	15.2	250
100	Immune checkpoint inhibition in urothelial carcinoma. Lancet, The, 2020, 395, 1522-1523.	6.3	2
101	Docetaxel with or without Ramucirumab after Platinum-Based Chemotherapy and Checkpoint Inhibitors in Advanced Urothelial Carcinoma: A Pre-Specified Subgroup Analysis from the Phase 3 RANGE Trial. Bladder Cancer, 2020, 6, 43-52.	0.2	2
102	Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. European Urology, 2020, 78, 29-42.	0.9	110
103	Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 12288-12294.	3.3	65
104	Clinical Characteristics and Outcome for Four SARS-CoV-2-infected Cancer Patients Treated with Immune Checkpoint Inhibitors. European Urology, 2020, 78, 276-280.	0.9	20
105	Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer. Journal of Clinical Oncology, 2020, 38, 2658-2666.	0.8	186
106	Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. Lancet, The, 2020, 395, 1268-1277.	6.3	311
107	Deferred Cytoreductive Nephrectomy Following Presurgical Vascular Endothelial Growth Factor Receptor-Targeted Therapy in Patients with Primary Metastatic Clear Cell Renal Cell Carcinoma: A Pooled Analysis of Prospective Trial Data. European Urology Oncology, 2020, 3, 168-173.	2.6	25
108	Treatment Choices for Front-line Metastatic Clear Cell Renal Cancer. European Urology, 2020, 77, 454-456.	0.9	6

#	ARTICLE	IF	CITATIONS
109	Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Na ⁺ ve Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 2506-2514.	3.2	20
110	Limitations of Available Studies Prevent Reliable Comparison Between Tumour Ablation and Partial Nephrectomy for Patients with Localised Renal Masses: A Systematic Review from the European Association of Urology Renal Cell Cancer Guideline Panel. <i>European Urology Oncology</i> , 2020, 3, 433-452.	2.6	43
111	Advice Regarding Systemic Therapy in Patients with Urological Cancers During the COVID-19 Pandemic. <i>European Urology</i> , 2020, 77, 667-668.	0.9	44
112	Patient-reported outcomes in a phase 2 study comparing atezolizumab alone or with bevacizumab vs sunitinib in previously untreated metastatic renal cell carcinoma. <i>BJU International</i> , 2020, 126, 73-82.	1.3	19
113	ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer. <i>Trials</i> , 2020, 21, 344.	0.7	7
114	The Efficacy of Sunitinib Treatment of Renal Cancer Cells Is Associated with the Protein PHAX In Vitro. <i>Biology</i> , 2020, 9, 74.	1.3	2
115	Five-Factor Prognostic Model for Survival of Post-Platinum Patients with Metastatic Urothelial Carcinoma Receiving PD-L1 Inhibitors. <i>Journal of Urology</i> , 2020, 204, 1173-1179.	0.2	47
116	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	11
117	IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5000-5000.	0.8	43
118	Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1370-1385.	5.1	594
119	Molecular and histopathology directed therapy for advanced bladder cancer. <i>Nature Reviews Urology</i> , 2019, 16, 465-483.	1.9	119
120	Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. <i>Nature Medicine</i> , 2019, 25, 1706-1714.	15.2	407
121	PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN. <i>Clinical Cancer Research</i> , 2019, 25, 6080-6088.	3.2	50
122	Cytoreductive nephrectomy in the current treatment algorithm. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591987902.	1.4	13
123	Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale. <i>Future Oncology</i> , 2019, 15, 929-941.	1.1	40
124	Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). <i>European Urology</i> , 2019, 76, 437-440.	0.9	29
125	Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 2404-2415.	6.3	778
126	Bladder cancer, a unique model to understand cancer immunity and develop immunotherapy approaches. <i>Journal of Pathology</i> , 2019, 249, 151-165.	2.1	80

#	ARTICLE	IF	CITATIONS
127	Primary Results from SAUL, a Multinational Single-arm Safety Study of Atezolizumab Therapy for Locally Advanced or Metastatic Urothelial or Nonurothelial Carcinoma of the Urinary Tract. <i>European Urology</i> , 2019, 76, 73-81.	0.9	117
128	The adjuvant treatment of kidney cancer: a multidisciplinary outlook. <i>Nature Reviews Nephrology</i> , 2019, 15, 423-433.	4.1	68
129	European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. <i>European Urology</i> , 2019, 75, 799-810.	0.9	1,022
130	Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2019, 380, 1116-1127.	13.9	2,319
131	Single-centre Experience of Patients with Metastatic Urothelial Cancer Treated with Chemotherapy Following Immune Checkpoint Inhibition. <i>European Urology Oncology</i> , 2019, 4, 659-662.	2.6	9
132	PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 1102.	1.1	17
133	The Impact of Cisplatin- or Non-Cisplatin-Containing Chemotherapy on Long-Term and Conditional Survival of Patients with Advanced Urinary Tract Cancer. <i>Oncologist</i> , 2019, 24, 1348-1355.	1.9	10
134	Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma. <i>European Journal of Cancer</i> , 2019, 108, 33-40.	1.3	96
135	Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib. <i>JAMA Oncology</i> , 2019, 5, 164.	3.4	329
136	The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer. <i>European Urology</i> , 2019, 75, 435-444.	0.9	97
137	5-factor prognostic model for survival of patients with metastatic urothelial carcinoma receiving three different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4552-4552.	0.8	3
138	A phase III, randomized, open label, multicenter, global study of efficacy and safety of durvalumab in combination with gemcitabine+cisplatin (G+C) for neoadjuvant treatment followed by durvalumab alone for adjuvant treatment in muscle-invasive bladder cancer (MIBC) (NIAGARA).. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4592-TPS4592.	0.8	6
139	A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).. <i>Journal of Clinical Oncology</i> , 2019, 37, 545-545.	0.8	40
140	Treatment-free survival (TFS) after discontinuation of first-line nivolumab (NIVO) plus ipilimumab (IPI) or sunitinib (SUN) in intention-to-treat (ITT) and IMDC favorable-risk patients (pts) with advanced renal cell carcinoma (aRCC) from CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 564-564.	0.8	10
141	Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.. <i>Journal of Clinical Oncology</i> , 2019, 37, 581-581.	0.8	14
142	Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 476-476.	0.8	0
143	Prevalence, disease-free (DFS) and overall (OS) survival of contemporary high-risk renal cell carcinoma (RCC) patients eligible for adjuvant checkpoint inhibitor trials: A RECUR database analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 636-636.	0.8	2
144	Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 478-478.	0.8	2

#	ARTICLE	IF	CITATIONS
145	Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5077-5077.	0.8	0
146	Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. <i>Lancet Oncology</i> , The, 2018, 19, 451-460.	5.1	228
147	TGF β 2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. <i>Nature</i> , 2018, 554, 544-548.	13.7	3,359
148	Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer. <i>JAMA Oncology</i> , 2018, 4, 537.	3.4	104
149	Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. <i>Lancet</i> , The, 2018, 391, 748-757.	6.3	1,142
150	Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2018, 378, 1277-1290.	13.9	3,334
151	Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer. <i>European Urology</i> , 2018, 73, 149-152.	0.9	93
152	Updated European Association of Urology Guidelines: Recommendations for the Treatment of First-line Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2018, 73, 311-315.	0.9	138
153	Anti-Programmed Cell Death 1/Ligand 1 (PD-1/PD-L1) Antibodies for the Treatment of Urothelial Carcinoma: State of the Art and Future Development. <i>Clinical Genitourinary Cancer</i> , 2018, 16, 117-129.	0.9	28
154	Quality of Life Outcomes for Cabozantinib Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma: METEOR Phase III Randomized Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 757-764.	0.8	43
155	Novel Agents and Drug Development Needs in Advanced Clear Cell Renal Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3639-3644.	0.8	9
156	Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 850-858.	0.8	288
157	Neoadjuvant vs. Adjuvant Chemotherapy in Muscle Invasive Bladder Cancer (MIBC): Analysis From the RISC Database. <i>Frontiers in Oncology</i> , 2018, 8, 463.	1.3	27
158	Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment. <i>Journal of Experimental Medicine</i> , 2018, 215, 2748-2759.	4.2	34
159	Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 663-669.	2.9	66
160	A Joint Statement from the European Association of Urology Renal Cell Cancer Guidelines Panel and the International Kidney Cancer Coalition: The Rejection of Ipilimumab and Nivolumab for Renal Cancer by the Committee for Medicinal Products for Human Use Does not Change Evidence-based Guideline Recommendations. <i>European Urology</i> , 2018, 74, 849-851.	0.9	3
161	Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma. <i>European Urology</i> , 2018, 74, 805-809.	0.9	80
162	The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma. <i>British Journal of Cancer</i> , 2018, 119, 160-163.	2.9	39

#	ARTICLE	IF	CITATIONS
163	Role of Checkpoint Inhibition in Localized Bladder Cancer. <i>European Urology Oncology</i> , 2018, 1, 190-198.	2.6	26
164	Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma. <i>Nature Medicine</i> , 2018, 24, 749-757.	15.2	900
165	Patient-reported outcomes (PROs) in IMmotion151: Atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun) in treatment (tx) naive metastatic renal cell carcinoma (mRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 4511-4511.	0.8	12
166	A phase Ia study of safety and clinical activity of atezolizumab (atezo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 187-187.	0.8	7
167	Results of POUT: A phase III randomised trial of perioperative chemotherapy versus surveillance in upper tract urothelial cancer (UTUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 407-407.	0.8	59
168	Atezolizumab (atezo) vs. chemotherapy (chemo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Immune biomarkers, tumor mutational burden (TMB), and clinical outcomes from the phase III IMvigor211 study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 409-409.	0.8	31
169	New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.. <i>Journal of Clinical Oncology</i> , 2018, 36, 413-413.	0.8	10
170	Quality-of-life (QoL) in RANGE: A phase 3 study of ramucirumab (RAM) plus docetaxel (DOC) versus placebo (P) plus DOC in platinum-refractory locally advanced or metastatic urothelial carcinoma (UC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 419-419.	0.8	4
171	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 426-426.	0.8	3
172	Docetaxel with or without ramucirumab after immune checkpoint inhibition in platinum-refractory metastatic urothelial carcinoma (mUC): Prespecified subgroup analysis from the phase 3 RANGE trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, 434-434.	0.8	10
173	IMmotion151: A Randomized Phase III Study of Atezolizumab Plus Bevacizumab vs Sunitinib in Untreated Metastatic Renal Cell Carcinoma (mRCC). <i>Journal of Clinical Oncology</i> , 2018, 36, 578-578.	0.8	164
174	Clinical outcome of patients (Pts) with metastatic renal cell carcinoma (mRCC) progressing on front-line immune-oncology based combination (IO-COMBO) regimens.. <i>Journal of Clinical Oncology</i> , 2018, 36, 613-613.	0.8	6
175	Imaging modalities used for follow-up of localized renal cell carcinoma (RCC) and subsequent effect on overall survival after recurrence: RECUR-database analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 637-637.	0.8	2
176	Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 645-645.	0.8	1
177	A phase 3 trial to compare efficacy and safety of lenvatinib in combination with everolimus or pembrolizumab versus sunitinib alone in first-line treatment of patients with metastatic renal cell carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS706-TPS706.	0.8	8
178	Phase 3, randomized, double-blind trial of pembrolizumab in the adjuvant treatment of renal cell carcinoma (RCC): KEYNOTE-564.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS712-TPS712.	0.8	5
179	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 448-448.	0.8	0
180	Epigenetic sampling effects: nephrectomy modifies the clear cell renal cell cancer methylome. <i>Cellular Oncology (Dordrecht)</i> , 2017, 40, 293-297.	2.1	2

#	ARTICLE	IF	CITATIONS
181	A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now. <i>Cancer Treatment Reviews</i> , 2017, 54, 58-67.	3.4	324
182	Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer. <i>Angiogenesis</i> , 2017, 20, 205-215.	3.7	59
183	Reply to Pontus Eriksson, Gottfrid Sjörydahl, and Fredrik Liedberg's Letter to the Editor re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. <i>J Clin Oncol</i> 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder Cancer is Also Needed. <i>European Urology</i> , 2017, 72, e137-e138.	0.9	3
184	Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , 2017, 389, 67-76.	6.3	1,728
185	Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 48-55.	0.8	165
186	First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology, The</i> , 2017, 18, 1483-1492.	5.1	1,034
187	Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. <i>Lancet, The</i> , 2017, 390, 2266-2277.	6.3	153
188	Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma. <i>JAMA Oncology</i> , 2017, 3, e172411.	3.4	750
189	Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer. <i>BMC Medicine</i> , 2017, 15, 118.	2.3	8
190	Randomized Phase II Study Investigating Pazopanib Versus Weekly Paclitaxel in Relapsed or Progressive Urothelial Cancer. <i>Journal of Clinical Oncology</i> , 2017, 35, 1770-1777.	0.8	27
191	First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. <i>Journal of Clinical Oncology</i> , 2017, 35, 4504-4504.	0.8	35
192	Role of targeted therapy in combination with surgery in renal cell carcinoma. <i>International Journal of Urology</i> , 2016, 23, 5-12.	0.5	18
193	European Association of Urology Guidelines for Clear Cell Renal Cancers That Are Resistant to Vascular Endothelial Growth Factor Receptor-Targeted Therapy. <i>European Urology</i> , 2016, 70, 705-706.	0.9	34
194	Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. <i>BMC Medicine</i> , 2016, 14, 185.	2.3	29
195	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. <i>Lancet Oncology, The</i> , 2016, 17, 917-927.	5.1	789
196	Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. <i>JAMA Oncology</i> , 2016, 2, 1303.	3.4	67
197	<i>HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1371-1377.	3.2	80
198	Atezolizumab, an Anti-Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study. <i>Journal of Clinical Oncology</i> , 2016, 34, 833-842.	0.8	517

#	ARTICLE	IF	CITATIONS
199	A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2016, 69, 450-456.	0.9	80
200	Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy. <i>European Urology</i> , 2016, 69, 4-6.	0.9	85
201	Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 172-183.	1.9	35
202	Systematic Review and Meta-analysis of Diagnostic Accuracy of Percutaneous Renal Tumour Biopsy. <i>European Urology</i> , 2016, 69, 660-673.	0.9	412
203	Dynamic epigenetic changes to <i>VHL</i> occur with sunitinib in metastatic clear cell renal cancer. <i>Oncotarget</i> , 2016, 7, 25241-25250.	0.8	14
204	Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: A systematic review and meta-analysis of clinical trials in advanced cancer patients. <i>European Journal of Cancer</i> , 2015, 51, 1293-1302.	1.3	45
205	EAU Guidelines on Renal Cell Carcinoma: 2014 Update. <i>European Urology</i> , 2015, 67, 913-924.	0.9	2,445
206	Salvage high-dose chemotherapy for germ cell tumors. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 355-362.	0.8	12
207	Elevating the Horizon: Emerging Molecular and Genomic Targets in the Treatment of Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 410-420.	0.9	17
208	Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial. <i>Clinical Cancer Research</i> , 2015, 21, 1071-1077.	3.2	217
209	Sunitinib Treatment Exacerbates Intratumoral Heterogeneity in Metastatic Renal Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4212-4223.	3.2	33
210	Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. <i>New England Journal of Medicine</i> , 2015, 373, 1814-1823.	13.9	1,004
211	Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. <i>Cancer</i> , 2015, 121, 2586-2593.	2.0	155
212	Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. <i>Journal of Clinical Oncology</i> , 2015, 33, 3018-3028.	0.8	63
213	A Systematic Review of Sequencing and Combinations of Systemic Therapy in Metastatic Renal Cancer. <i>European Urology</i> , 2015, 67, 100-110.	0.9	122
214	First prospective, open-label, phase 2 study of sipuleucel-T (sip-T) in European men with metastatic, castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2015, 33, e16015-e16015.	0.8	0
215	Development and validation of an ultra-high performance LC-MS/MS assay for intracellular SN-38 in human solid tumour cell lines: Comparison with a validated HPLC-fluorescence method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2014, 969, 213-218.	1.2	9
216	MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. <i>Nature</i> , 2014, 515, 558-562.	13.7	2,109

#	ARTICLE	IF	CITATIONS
217	Reply to S. Barni et al and M. Sun et al. <i>Journal of Clinical Oncology</i> , 2014, 32, 3783-3784.	0.8	1
218	Assessing the Response to Targeted Therapies in Renal Cell Carcinoma: Technical Insights and Practical Considerations. <i>European Urology</i> , 2014, 65, 766-777.	0.9	32
219	Sequential Targeted Therapy After Pazopanib Therapy in Patients With Metastatic Renal Cell Cancer: Efficacy and Toxicity. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 262-269.	0.9	9
220	Local treatments for metastases of renal cell carcinoma: a systematic review. <i>Lancet Oncology</i> , The, 2014, 15, e549-e561.	5.1	265
221	The Molecular Biology of Renal Cancer: Another Piece of the Puzzle. <i>European Urology</i> , 2014, 66, 85-86.	0.9	4
222	Carbonic Anhydrase 9 Expression Increases with Vascular Endothelial Growth Factor-Targeted Therapy and Is Predictive of Outcome in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2014, 66, 956-963.	0.9	38
223	Mammalian Target of Rapamycin Inhibitors: The Beginning of the End or the End of the Beginning?. <i>European Urology</i> , 2014, 66, 282-283.	0.9	0
224	A phase Ib study investigating the combination of everolimus and dovitinib in vascular endothelial growth factor refractory clear cell renal cancer. <i>European Journal of Cancer</i> , 2014, 50, 2057-2064.	1.3	15
225	A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 4525-4525.	0.8	12
226	Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).. <i>Journal of Clinical Oncology</i> , 2014, 32, 5011-5011.	0.8	49
227	Is there an anti-androgen withdrawal effect with enzalutamide?. <i>Journal of Clinical Oncology</i> , 2014, 32, 200-200.	0.8	1
228	Phase 3 randomized study of cabozantinib (XL184) versus everolimus in subjects with clear cell renal cell carcinoma (METEOR).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS4601-TPS4601.	0.8	1
229	London Cancer's multidisciplinary approach to urological cancer. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 609-610.	12.5	6
230	The conundrum of clinical trials in adult germ-cell tumours. <i>Lancet Oncology</i> , The, 2013, 14, 14-15.	5.1	4
231	The Use of Reverse Phase Protein Arrays (RPPA) to Explore Protein Expression Variation within Individual Renal Cell Cancers. <i>Journal of Visualized Experiments</i> , 2013, , .	0.2	8
232	Pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer: A clinical and biomarker study.. <i>Journal of Clinical Oncology</i> , 2013, 31, 4508-4508.	0.8	4
233	Management of Favorable-Risk Patients With Metastatic Renal Cell Carcinoma: When to Start and When to Stop Targeted Therapy. <i>Clinical Genitourinary Cancer</i> , 2012, 10, 213-218.	0.9	9
234	An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer. <i>European Journal of Cancer</i> , 2012, 48, 3171-3176.	1.3	12

#	ARTICLE	IF	CITATIONS
235	The management of low-stage non-seminomatous germ cell tumors. <i>Oncology Reviews</i> , 2012, 6, 19.	0.8	0
236	Outcome of rapid disease progression in the treatment break following cytoreductive nephrectomy (CN) after presurgical sunitinib in patients with primary metastatic renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 4611-4611.	0.8	1
237	Testicular germ cell tumors with bony metastases: Diagnosis, management, and outcomes (a case) <i>Tj ETQq1 1 0.784314 rgBT₂ /Overl</i>	0.8	0
238	The safety and efficacy of pazopanib prior to planned nephrectomy in metastatic clear cell renal cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 427-427.	0.8	5
239	The efficacy of irinotecan, paclitaxel, and oxaliplatin (IPO) in relapsed germ cell tumours: A non-cisplatin-based regimen.. <i>Journal of Clinical Oncology</i> , 2012, 30, 4529-4529.	0.8	0
240	Stage I Nonseminomatous Germ Cell Tumor of the Testis: More Questions than Answers?. <i>Hematology/Oncology Clinics of North America</i> , 2011, 25, 517-527.	0.9	4
241	What can molecular pathology contribute to the management of renal cell carcinoma?. <i>Nature Reviews Urology</i> , 2011, 8, 255-265.	1.9	66
242	Is High Dose Therapy Superior to Conventional Dose Therapy as Initial Treatment for Relapsed Germ Cell Tumors? The TIGER Trial. <i>Journal of Cancer</i> , 2011, 2, 374-377.	1.2	55
243	The Outcome of Patients Treated with Sunitinib Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer. <i>European Urology</i> , 2011, 60, 448-454.	0.9	104
244	Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 6021-6028.	3.2	123
245	The Effect of Sunitinib on Immune Subsets in Metastatic Clear Cell Renal Cancer. <i>Urologia Internationalis</i> , 2011, 86, 53-59.	0.6	15
246	THE APPLICATION OF THE NATIONAL INSTITUTE OF CLINICAL EXCELLENCE GUIDELINES FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN THE UNITED KINGDOM: FRIEND OR FOE?. <i>BJU International</i> , 2010, 106, 453-457.	1.3	2
247	Highly Active Antiretroviral Therapy and the Incidence of Non-AIDS-Defining Cancers in People With HIV Infection. <i>Journal of Clinical Oncology</i> , 2009, 27, 884-890.	0.8	355
248	The efficacy and safety of irinotecan cisplatin and mitomycin chemotherapy in sunitinib pre-treated metastatic clear cell renal cancer. <i>OncoTargets and Therapy</i> , 2008, 1, 35.	1.0	2
249	A Comparison of the Platinum Analogues in Bladder Cancer Cell Lines. <i>Urologia Internationalis</i> , 2007, 79, 67-72.	0.6	14
250	Hepatocellular cancer in HIV-infected individuals: tomorrow's problem?. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1553-1558.	1.1	14
251	Non-AIDS-defining cancers in people with HIV infection: a sleeping giant?. <i>Journal of HIV Therapy</i> , 2006, 11, 57-60.	0.6	3
252	Cannabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. <i>Blood</i> , 2005, 105, 1214-1221.	0.6	67